Needham & Company LLC Lowers NewAmsterdam Pharma (NASDAQ:NAMS) Price Target to $42.00

NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) had its price objective cut by analysts at Needham & Company LLC from $46.00 to $42.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s price objective would indicate a potential upside of […]

Mar 1, 2025 - 09:45

NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) had its price objective cut by analysts at Needham & Company LLC from $46.00 to $42.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s price objective would indicate a potential upside of […]